Business Details
15 Years
experience
Personalized Cancer Treatment Through Genetic Insight
At Mira DX, we are pioneers in the field of personalized cancer treatment, leveraging groundbreaking genetic research to transform how physicians tailor therapies for individual patients. Founded by internationally recognized researchers Dr. Frank Slack and Dr. Joanne Weidhaas, our work focuses on microRNA biomarkers that predict treatment responses and toxicity risks, enabling safer and more effective care. With over 30 years of combined research experience, our team has developed proprietary tests like PROSTOX, PREVIOTOX, and the KRAS-variant panel, which guide treatment decisions for prostate cancer, immunotherapy, and hereditary cancer risks. Partnering with leading universities and clinics, we bridge the gap between genetic discovery and clinical application, ensuring physicians have actionable data to personalize radiation therapy, immunotherapy, and targeted treatments.Our commitment to advancing precision medicine is reflected in our CLIA-certified and CAP-accredited laboratory, which adheres to the highest standards of quality and innovation. By identifying inherited genetic variants that influence treatment outcomes, we empower patients and providers to make informed decisions that minimize side effects and maximize therapeutic efficacy. Our research-driven approach has been validated through extensive peer-reviewed publications and collaborations, including the MIRAGE trial, which confirmed the predictive power of our biomarkers in modern radiation therapy. As a leader in microRNA-based diagnostics, we continue to expand our pipeline to address unmet needs in oncology, ensuring every patient receives care tailored to their unique genetic profile.
Services
PROSTOX
PREVIOTOX
KRAS-variant Testing
Radiation Genetics
Immunotherapy Biomarkers
Details
- Year established: 2011
Highlights and features
- We offer 30+ years of pioneering research in microRNA biomarkers.
- Our tests are validated by peer-reviewed studies and clinical trials.
- We provide actionable insights to reduce radiation and immunotherapy toxicity.
- Our CLIA-certified lab ensures the highest diagnostic accuracy standards.
- We partner with leading academic institutions for continuous innovation.
Associations and certifications
- CLIA certification
- CAP accreditation
Services
PROSTOX
PROSTOX identifies prostate cancer patients at risk for late radiation toxicity using microRNA biomarkers. This test helps physicians select the safest radiation regimen, reducing side effects while maintaining treatment efficacy. Clinically validated through studies like the MIRAGE trial, it supports personalized decision-making for SBRT and CFRT options.
PREVIOTOX
PREVIOTOX predicts immune-related adverse events in patients receiving anti-PD1/PDL1 therapies. By analyzing germline genetic mutations, it identifies patients with up to 9-fold increased risk of severe side effects, enabling proactive treatment adjustments. This panel supports safer immunotherapy use across multiple cancer types.
KRAS-variant Testing
KRAS-variant testing assesses inherited genetic risks for breast, ovarian, and lung cancers. It guides prevention strategies like estrogen replacement therapy and informs treatment decisions for patients with cancers showing differential responses to targeted therapies.
Radiation Genetics
Our radiation genetics program identifies biomarkers that influence individual responses to radiation therapy. By analyzing microRNA variants, we help clinicians optimize treatment plans for cancers including prostate, head and neck, and rectal carcinomas, minimizing toxicity risks.
Immunotherapy Biomarkers
We develop biomarkers to predict immunotherapy outcomes, focusing on genetic factors that affect response to checkpoint inhibitors. These tools help physicians balance therapeutic efficacy with risks of immune-related adverse events across multiple tumor types.
People
Frank Slack, PhD
Co-Founder
Dr. Slack is a leading microRNA researcher and director of the Institute for RNA Medicine at Beth Israel Deaconess Medical Center. His discovery of let-7 microRNA's role in cancer regulation laid the foundation for Mira DX's biomarker platform. He has authored over 250 publications and holds an 84 H-index.
Joanne Weidhaas, MD, PhD
Co-Founder
Dr. Weidhaas co-discovered the KRAS-variant biomarker and leads translational research at UCLA's Department of Radiation Oncology. With 25+ years in research and 20+ years in clinical practice, she bridges genetic discovery with patient care, holding 125+ publications and a 38 H-index.
Questions
What types of cancer does MiraDx focus on?
We specialize in prostate cancer (PROSTOX), immunotherapy-related cancers (PREVIOTOX), and hereditary cancers linked to the KRAS-variant, including breast, ovarian, and lung cancers.
How do MiraDx tests improve treatment outcomes?
Our biomarker tests identify genetic predispositions to treatment toxicity and efficacy, enabling physicians to select optimal therapies while minimizing severe side effects like radiation damage or immune-related adverse events.
Is financial assistance available for testing?
Yes, our Financial Assistance Program offers reduced pricing based on household income, with eligible patients paying as little as $0 and a maximum of $395 out-of-pocket.
How are test results used in clinical practice?
Physicians use our reports to guide treatment decisions, such as selecting radiation regimens with lower toxicity risks or adjusting immunotherapy protocols based on predicted adverse event probabilities.
What accreditations does MiraDx hold?
Our laboratory maintains CLIA certification (#07D2006340) and CAP accreditation (#8861922), ensuring compliance with the highest standards for clinical laboratory testing.
Reviews (3)
Ken Shu
May 21, 2021
Report
The staff is very rude and unprofessional! The people who take personal information for covid testing have bad attitudes and even threaten people if they dont give them information they already have.
Steve Kinsey
Sep 01, 2020
Report
I got a Covid test by them and it was back within hours. Amazing and speedy service! Highly recommend!
Cord Lambrecht
Aug 23, 2020
Report
Took a covid test almost two weeks ago. Still waiting on the results. Will update if I hear anything of if I can get through on the broken phone line.
Update: I heard back, along with others who took the test on the same day. This company is nearly two weeks behind on testing, as of Monday, May 4th. I appreciate that they're looking to help but feel that if they are unprepared they should not take on duties like this irresponsibly.
Update: I heard back, along with others who took the test on the same day. This company is nearly two weeks behind on testing, as of Monday, May 4th. I appreciate that they're looking to help but feel that if they are unprepared they should not take on duties like this irresponsibly.